All you need to know about the FDA’s Draft Guidance on Diversity Action Plans
The U.S. Food and Drug Administration’s (FDA) draft guidance on Diversity Action Plans (DAPs) is a significant step towards addressing the underrepresentation of diverse populations in clinical research. Released in June 2024, this guidance aligns with broader efforts...
Biomapas Announces Strategic Partnership to Drive Future Growth
Press Release Biomapas Announces Strategic Partnership to Drive Future Growth Biomapas, a leading provider of clinical research, pharmacovigilance (PV), regulatory affairs (RA), medical information (MI), and quality assurance (QA) services across Europe, is pleased to...
Diversity in Clinical Trials: Significance & Challenges
Diversity in Clinical Trials: Significance & Challenges By Jan Filakovsky, CEO of Biomapas Diversity in clinical trials is crucial in ensuring that research findings are broadly applicable, and in avoiding treatments that are ineffective or even harmful to...
Partnering for Success: Specialised Rescue Studies in Georgia
Discover how Biomapas supported three pharmaceutical companies in achieving their recruitment goals and explore the benefits of conducting clinical trials in Georgia. With over 400 international trials, 66 active institutions, and 128 experienced Principal...





